EMBOLISATION AGENT THAT CAN SEAL OFF VARICOSITY AND/OR HEMORRHOIDS

Abstract

An embolisation agent is a mixture of n-butyl cyanoacrylate and octyl cyanoacrylate having CPS ratios between 1-1000 cps. The invention is particularly related to a medical method and medical device used in treatments which enable to obturate, superficial varicosity, Pake and hemorrhoids with embolisation. By means of the device and method subject to the invention the progression of varicose veins, Pake and internal and external hemorrhoids can be stopped, obturated or clogged.

Claims

1. An embolisation agent comprising a mixture of n-butyl cyanoacrylate and octyl cyanoacrylate having CPS ratios between 1-1000 cps.

2. An embolisation agent comprising a mixture of n-butyl, cyanoacrylate, octyl cyanoacrylate and ethyl cyanoacrylate having CPS ratios between 1-1000 cps.

3. The embolisation agent according to claim 1, wherein, a ratio of n-butyl cyanoacrylate to octyl cyanoacrylate is 1:1.

4. The embolisation agent according to claim 1, wherein, a ratio of n-butyl cyanoacrylate to octyl cyanoacrylate is 1:2.

5. The embolisation agent according to claim 1, wherein, a ratio of n-butyl cyanoacrylate to octyl cyanoacrylate is 1:3.

6. The embolisation agent according to claim 1, wherein, a ratio of n-butyl cyanoacrylate to octyl cyanoacrylate is 1:4.

7. The embolisation agent according to claim 1, wherein, a ratio of n-butyl cyanoacrylate to octyl cyanoacrylate is 1:5.

8. The embolisation agent according to claim 1, wherein, a ratio of n-butyl cyanoacrylate to octyl cyanoacrylate is 1:6.

9. The embolisation agent according to claim 1, wherein, a ratio of n-butyl cyanoacrylate to octyl cyanoacrylate is 1:7.

10. The embolisation agent according to claim 1, wherein, a ratio of n-butyl cyanoacrylate to octyl cyanoacrylate is 1:8.

11. The embolisation agent according to claim 1, wherein, a ratio of n-butyl cyanoacrylate to octyl cyanoacrylate is 1:9.

12. The embolisation agent according to claim 1, wherein, a ratio of n-butyl cyanoacrylate to octyl cyanoacrylate is 1:10.

13. A method for treating varicose veins, haemorrhoids or surface veins, the method comprising: injecting an embolisation agent into a vein, wherein the embolisation agent is a mixture of n-butyl cyanoacrylate and octyl cyanoacrylate having CPS ratios between 1-1000 cps; applying a pressure to the vein for a predetermined time; and sealing off the vein.

14. The embolisation agent according to claim 1, wherein the embolisation agent further comprises dimethylsulfuroxide within the cyanoacrylate solvent.

15. The embolisation agent according to claim 2, wherein the embolisation agent further comprises dimethylsulfuroxide within the cyanoacrylate solvent.

16. The embolisation agent according to claim 3, wherein the embolisation agent further comprises dimethylsulfuroxide within the cyanoacrylate solvent.

17. The embolisation agent according to claim 4, wherein the embolisation agent further comprises dimethylsulfuroxide within the cyanoacrylate solvent.

18. The embolisation agent according to claim 5, wherein the embolisation agent further comprises dimethylsulfuroxide within the cyanoacrylate solvent.

19. The embolisation agent according to claim 6, wherein the embolisation agent further comprises dimethylsulfuroxide within the cyanoacrylate solvent.

20. The embolisation agent according to claim 7, wherein the embolisation agent further comprises dimethylsulfuroxide within the cyanoacrylate solvent.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0019] The embolisation agent subject to the invention is an n-butyl cyano acrylate and octyl cyanoacrylate mixture that is to be applied particularly for varicose veins and hemorrhoids. The n-butyl cyanoacrylate:octyl cyanoacrylate ratios in the mixture have been produced having a ratio of 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10 and multiples thereof with the CPS (centipoise) ratios of 1-1000 cps.

[0020] The embolisation agents used in the invention are materials that can be used in the body in comparison to normal acrylates, that show rapid effects at the area of process and that, can stay soft. Moreover said agent is softer than the acrylates used in other areas of the body and it is rapid acting and it can be delivered by means of an injector, The affects to the surrounding tissue in applications to sensitive areas such as the anal region or applications close to the skin, are reduced by means of the invention, by decreasing the irritating effects of octyl cyanoacrylates and n-butyl cyanoacrylates. Additionally although the n-butyl groups are harder under the skin during sensitive applications, the octyl group remains soft. The n-butyl group makes adhesion faster as it has a higher irritating effect. The aim here, is to provide a mixture having a certain ratio, in order to optimize features such as the irritating effect, adhesion and being able to remain soft.

[0021] The storage conditions of the end product are between 6-24° C., and the product is delivered to the user inside standard ampoules.

[0022] The embolisation agent which is a mixture of n-butyl cyanoacrylate and octyl cyanoacrylate, has been developed in order to be used during the embolisation process carried out in relation to the treatment of varicose veins and/or hemorrhoids. Moreover it is also possible to use the invention during aneurism embolisation.

[0023] An embolisation agent comprising an n-butyl cyanoacrylate, octyl cyanoacrylate and ethyl cyanoacrylate mixture having CPS ratios between 1-1000 cps has been developed which shall be used in treating hemorrhoids and surface veins.